Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacob P Hoj

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Proceedings of the National Academy of Sciences of the United States of America|April 11, 2023
ABL kinases regulate the stabilization of HIF-1α and MYC through CPSF1Benjamin Mayro, Jacob P Hoj, Christian G Cerda-Smith, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
MCB-613 exploits a collateral sensitivity in drug resistant <i>EGFR</i>-mutant non-small cell lung cancer through covalent inhibition of KEAP1Christopher F Bassil, Gray R Anderson, Benjamin Mayro, et al.
Nature Communications|January 14, 2026
EGFR inhibitor-resistant lung cancers exhibit collateral sensitivity to a covalent, cysteine-independent KEAP1 oligomerizing molecular bridgeChristopher F Bassil, Kerry Dillon, Gray R Anderson, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Proceedings of the National Academy of Sciences of the United States of America|April 11, 2023
ABL kinases regulate the stabilization of HIF-1α and MYC through CPSF1Benjamin Mayro, Jacob P Hoj, Christian G Cerda-Smith, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
MCB-613 exploits a collateral sensitivity in drug resistant <i>EGFR</i>-mutant non-small cell lung cancer through covalent inhibition of KEAP1Christopher F Bassil, Gray R Anderson, Benjamin Mayro, et al.
Nature Communications|January 14, 2026
EGFR inhibitor-resistant lung cancers exhibit collateral sensitivity to a covalent, cysteine-independent KEAP1 oligomerizing molecular bridgeChristopher F Bassil, Kerry Dillon, Gray R Anderson, et al.
Pageof 2